{"nctId":"NCT00485758","briefTitle":"Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)","startDateStruct":{"date":"2007-07"},"conditions":["Diabetes Mellitus Type 2"],"count":796,"armGroups":[{"label":"1","type":"OTHER","interventionNames":["Drug: ER niacin/laropiprant"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator : placebo (unspecified)"]}],"interventions":[{"name":"ER niacin/laropiprant","otherNames":["MK0524A","CORDAPTIVEâ„¢","laropiprant (+) niacin"]},{"name":"Comparator : placebo (unspecified)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients between the ages of 18 to 80 years with Type 2 Diabetes who are on a stable dose of antidiabetic medication for at least 3 months\n\nExclusion Criteria:\n\n* Patients taking Cholestin, niacin (\\>50 mg/day), fibrate therapy, hormonal contraceptives, intermittent Hormone Replacement Therapy, or certain corticosteroids\n* Patients with any of the following conditions: active liver disease or kidney disease, poorly controlled high blood pressure, active peptic ulcer, or other heart or blood diseases\n* Patients with abnormal laboratory results from a blood test that will be given before starting the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo","description":"After 12 Weeks of treatment, to assess the reduction of low-density lipoprotein cholesterol in patients with Type 2 diabetes when compared to placebo","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.8","spread":null},{"groupId":"OG001","value":"2.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in High Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo","description":"After 12 weeks of treatment, to assess the increase of high-density lipoprotein cholesterol in patients with Type 2 diabetes when compared to placebo","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.4","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Triglycerides in Patients With Type 2 Diabetes When Compared to Placebo","description":"after 12 weeks of treatment, to assess the reduction of triglycerides in patients with Type 2 diabetes when compared to placebo","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.2","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":26,"n":449},"commonTop":["Flushing","Pruritus","Blood glucose increased","Diarrhoea","Nasopharyngitis"]}}}